Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
/PRNewswire/ -- Amgen (NASDAQ: AMGN) a annoncé aujourd'hui que la Commission européenne (CE) avait approuvé UPLIZNA (inebilizumab) comme traitement d'appoint
/PRNewswire/ -- Amgen (NASDAQ: AMGN) anunció hoy que la Comisión Europea (CE) ha aprobado UPLIZNA (inebilizumab) como tratamiento complementario al tratamiento
Eubel Brady and Suttman Asset Management Inc. purchased a new position in shares of Amgen Inc. (NASDAQ: AMGN) in the undefined quarter, according to its most recent filing with the Securities and Exch

2 Urgent Sells And 2 No Brainer Dividend Buys

04:06pm, Wednesday, 11'th Feb 2026
One thing I've learned is the pendulum always swings. It is in our best approach to sell high and buy low. This has worked well for us, as our returns suggest.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Advisors Asset Management Inc. lowered its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 1.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities an
Wealthfront Advisers LLC boosted its position in Amgen Inc. (NASDAQ: AMGN) by 22.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange C
Allegheny Financial Group cut its position in shares of Amgen Inc. (NASDAQ: AMGN) by 76.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SE
Alps Advisors Inc. raised its holdings in Amgen Inc. (NASDAQ: AMGN) by 63.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund own
Amgen Inc. (NASDAQ: AMGN - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are currently covering the stock, MarketBeat reports. One equities
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Candriam S.C.A. lessened its position in shares of Amgen Inc. (NASDAQ: AMGN) by 12.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange
Smartleaf Asset Management LLC boosted its holdings in Amgen Inc. (NASDAQ: AMGN) by 36.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned
Profund Advisors LLC decreased its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 3.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SE
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE